Physician profile
John H Webb
NPI 1801804133
$11,063.54
in general payments reported to CMS, 2019-2025
41 companies · $2,534 in 2025
The $2,534 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,443 · 2020: $257 · 2021: $1,003 · 2022: $1,609 · 2023: $1,599 · 2024: $2,618 · 2025: $2,534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,525 · Education: $226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,525.42 |
| Education | $225.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,776.83 | 2019-2025 | Linzess, Skyrizi, Viberzi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,138.61 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,085.88 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $902.59 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Genzyme Corporation | $787.20 | 2022-2025 | |
| Gilead Sciences, INC. | $568.81 | 2019-2025 | |
| Pfizer INC. | $434.87 | 2019-2025 | |
| Qol Medical, LLC | $389.36 | 2021-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $333.00 | 2019-2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $327.21 | 2019-2025 | Ocaliva |
| Lilly USA, LLC | $318.89 | 2024-2025 | Omvoh, Zepbound |
| Daiichi Sankyo INC. | $276.18 | 2019-2025 | Injectafer |
| Aimmune Therapeutics, INC. | $267.07 | 2024-2025 | Zenpep, Vowst |
| Regeneron Healthcare Solutions, INC. | $224.12 | 2023-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $190.37 | 2021-2024 | Linzess |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.